Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma

Yajun Li, Ruolan Zeng, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6394.

https://doi.org/10.1182/blood-2024-202471

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

Progression of Disease within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Yizi He, Caiqin Wang, Yajun Li, Ruolan Zeng, Chen Xia, Yixue Li, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2024-202252

Published: 2024

Journal Articles

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Zhiming Li, Jun Fang, Huilai Zhang, Wei Wang, Hui Li, Hui Zhou, Liqun Zou, Hong Cen, Wen Shujuan, Wuping Li, Peng Sun, Panpan LIU, Hang Yang, Yu Wang

Blood (2024) 144 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2024-204292

Published: 2024

Journal Articles

Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis

Yixue Li, Ruolan Zeng, Chen Xia, Yajun Li, Yizi He, Caiqin Wang, Hui Zhou

Blood (2024) 144 (Supplement 1): 6465.

https://doi.org/10.1182/blood-2024-204718

Published: 2024

Journal Articles

Prophylaxis with Thiotepa and High-Dose Methotrexate Showed Low CNS Relapse Rate in Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse

Ruolan Zeng, Zhou Ouyang, Yajun Li, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Yixue Li, Yinhua Liu, Weiqiang Tang, Qianying Ouyang, Liang Liang, Chang Su, Guige Lu, Xueting Zhu, Qianyu Hu, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6460.

https://doi.org/10.1182/blood-2024-202812

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Blood (2024) 144 (Supplement 1): 6355.

https://doi.org/10.1182/blood-2024-194674

Published: 2024

Journal Articles

Clinical Applications of Circulating Tumor DNA in the Diagnosis and Prognostic Stratification of Mantle Cell Lymphoma

Zhou Ouyang, Yajun Li, Ruolan Zeng, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6197.

https://doi.org/10.1182/blood-2024-201575

Published: 2024

Journal Articles

Targeting YTHDC1 Inhibited the Progression of Mantle Cell Lymphoma By Inhibiting the Expression of MYC Gene through m6A Modification

Hui Zhou, Li Wang, Ruicheng Yang, Guifeng Lin, Hailin Zhang, Ting Niu

Blood (2024) 144 (Supplement 1): 5821.

https://doi.org/10.1182/blood-2024-207319

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Chen Xia, Yajun Li, Zhongyi Sun, Lijun Huang, Ruolan Zeng, Yizi He, Caiqin Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2024-200882

Published: 2024

Journal Articles

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

Li Wang, Guo Zhang, Hui Zhou, Ting Niu

Blood (2024) 144 (Supplement 1): 4165.

https://doi.org/10.1182/blood-2024-207718

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Lugui Qiu, Zhuogang Liu, Shuhua Yi, Thanh Nguyen, Wen-Juan Yu, Keshu Zhou, Haiwen Huang, Udomsak Bunworasate, Man Huynh, Hui Zhou, Su-Peng Yeh, Yiqiu Wang, Xiaofeng Liu, Wei Fu

Blood (2024) 144 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2024-193476

Published: 2024

Journal Articles

Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing

Caiqin Wang, Yizi He, Yajun Li, Ruolan Zeng, Zhiming Li, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2024-204698

Published: 2024

Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei

Blood (2023) 142 (Supplement 1): 6240.

https://doi.org/10.1182/blood-2023-181503

Published: 2023

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Blood (2023) 142 (Supplement 1): 306.

https://doi.org/10.1182/blood-2023-180137

Published: 2023

NARROW

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Progression of Disease within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis

Prophylaxis with Thiotepa and High-Dose Methotrexate Showed Low CNS Relapse Rate in Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Clinical Applications of Circulating Tumor DNA in the Diagnosis and Prognostic Stratification of Mantle Cell Lymphoma

Targeting YTHDC1 Inhibited the Progression of Mantle Cell Lymphoma By Inhibiting the Expression of MYC Gene through m6A Modification

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

YL0712-3, a Novel ATR/ATM Inhibitor, Demonstrates Anti-Tumor Activity in TP53 Mutant DLBCL through Synthetic Lethality and Degradation of Mutant p53

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only